PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Vivek Narayan,Julie S Barber-Rotenberg,In-Young Jung,Simon F Lacey,Andrew J Rech,Megan M Davis,Wei-Ting Hwang,Priti Lal,Erica L Carpenter,Shannon L Maude,Gabriela Plesa,Neha Vapiwala,Anne Chew,Michael Moniak,Ronnie A Sebro,Michael D Farwell,Amy Marshall,Joan Gilmore,Lester Lledo,Karen Dengel,Sarah E Church,Tyler D Hether,Jun Xu,Mercy Gohil,Thomas H Buckingham,Stephanie S Yee,Vanessa E Gonzalez,Irina Kulikovskaya,Fang Chen,Lifeng Tian,Kyle Tien,Whitney Gladney,Christopher L Nobles,Hayley E Raymond,Prostate Cancer Cellular Therapy Program Investigators,Elizabeth O Hexner,Donald L Siegel,Frederic D Bushman,Carl H June,Joseph A Fraietta,Naomi B Haas,Diane Frazee,Mary Truran,Elizabeth Veloso,Holly McConville,Jonathan Aguedelo,Samantha Hower,Sophia Ngo,Julie Jadlowsky,J Joseph Melenhorst,Aoife Roche,John Everett,Minnal Gupta,Farzana Nazimuddin,Chelsie Bartoszek,Natalka Koterba,Rachael Reynolds,Farris Ellington,Christopher C Kloss,Jihyun Lee,Yangbing Zhao,John Scholler,James L Riley,Christina Bailey,Andrew White,Briana Hudson,Pearl Chang,Marcela V Maus,Bruce L Levine
DOI: https://doi.org/10.1038/s41591-022-01726-1
Abstract:Chimeric antigen receptor (CAR) T cells have demonstrated promising efficacy, particularly in hematologic malignancies. One challenge regarding CAR T cells in solid tumors is the immunosuppressive tumor microenvironment (TME), characterized by high levels of multiple inhibitory factors, including transforming growth factor (TGF)-β. We report results from an in-human phase 1 trial of castration-resistant, prostate cancer-directed CAR T cells armored with a dominant-negative TGF-β receptor (NCT03089203). Primary endpoints were safety and feasibility, while secondary objectives included assessment of CAR T cell distribution, bioactivity and disease response. All prespecified endpoints were met. Eighteen patients enrolled, and 13 subjects received therapy across four dose levels. Five of the 13 patients developed grade ≥2 cytokine release syndrome (CRS), including one patient who experienced a marked clonal CAR T cell expansion, >98% reduction in prostate-specific antigen (PSA) and death following grade 4 CRS with concurrent sepsis. Acute increases in inflammatory cytokines correlated with manageable high-grade CRS events. Three additional patients achieved a PSA reduction of ≥30%, with CAR T cell failure accompanied by upregulation of multiple TME-localized inhibitory molecules following adoptive cell transfer. CAR T cell kinetics revealed expansion in blood and tumor trafficking. Thus, clinical application of TGF-β-resistant CAR T cells is feasible and generally safe. Future studies should use superior multipronged approaches against the TME to improve outcomes.